A new study suggests memory T cells might protect some people infected with SARS-CoV-2 by remembering past encounters with other human coronaviruses. The finding might help explain why some people seem to fend off COVID-19 and may be less susceptible to becoming severely ill.
To come to this conclusion, researchers obtained and analyzed blood samples from 36 people who’d recently recovered from mild to severe COVID-19. All these individuals produced T cells that recognize multiple parts of SARS-CoV-2. They then compared this data to people who’d survived SARS. Interestingly, those memory T cells, acquired in response to SARS-CoV-1, also recognized parts of SARS-CoV-2.
Finally, the team looked at healthy individuals with no history of either COVID-19 or SARS. To their surprise, more than half had T cells that recognize one or more of the SARS-CoV-2 proteins being studied. It’s still not clear if this acquired immunity stemmed from previous infection with coronaviruses that cause the common cold or perhaps from exposure to other as-yet unknown coronaviruses.
Overall, the study makes clear that past experiences with coronavirus infections may have something important to tell us about COVID-19.
Late this afternoon, the National Institutes of Health announced preliminary phase 1 results of mRNA-1273, an investigational vaccine designed to protect against SARS-CoV-2, the virus that causes COVID-19. The vaccine candidate was one of the first to reach clinical trials. This was due in part to prior animal studies of related vaccines also developed collaboratively by NIH and Moderna Inc.
According to the NIH, the vaccine was generally well tolerated and prompted neutralizing antibody activity in healthy adults. mRNA-1273 is designed to induce neutralizing antibodies directed at a portion of the coronavirus “spike” protein, which the virus uses to bind to and enter human cells. A Phase 2 clinical trial of mRNA-1273 began enrollment in late May. Plans are underway to launch a Phase 3 efficacy trial in July 2020.
The National Institute of Allergy and Infectious Diseases (NIAID) today announced it has established a new clinical trials network. The network seeks to enroll thousands of volunteers to test a variety of investigational vaccines and monoclonal antibodies intended to protect people from COVID-19.
The COVID-19 Prevention Trials Network (COVPN) was established by merging four existing NIAID-funded clinical trials networks: the HIV Vaccine Trials Network, based in Seattle; the HIV Prevention Trials Network, based in Durham, N.C.; the Infectious Diseases Clinical Research Consortium, based in Atlanta; and the AIDS Clinical Trials Group, based in Los Angeles.
The first Phase 3 clinical trial the COVPN is expected to conduct will involve testing the investigational mRNA-1273 vaccine, developed by NIAID scientists and their collaborators at the biotechnology company Moderna, Inc., based in Cambridge, Massachusetts. That study is expected to begin this summer.
The National Institutes of Health is today hosting a livestream where NIH Director Dr. Francis Collins and NIAID Director Dr. Anthony Fauci discuss the status of the COVID-19 pandemic. They will also provide an update on progress to combat the disease. The live presentation will take place at 2:30 pm ET on the NIH Facebook and Twitter feeds. Those links can be found below.
Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, provided a dire warning today during a Senate committee hearing. “We are now having 40-plus thousand new cases a day. I would not be surprised if we go up to 100,000 a day if this does not turn around,” Fauci said in response to a question about the likely U.S. coronavirus death toll
Meanwhile, the European Union has confirmed that Americans will not be allowed to travel to the bloc of 27 countries when it reopens to some foreign travel Wednesday.
Washington Post: Fauci testifies new coronavirus cases could ‘go up to 100,000 a day’
The latest addition to AMP’s COVID-19 video series is now out. The short movie highlights and corrects many of the myths, conspiracy theories and untruths that have spread along with the novel coronavirus itself. As you might expect, the video focuses on some of the misleading claims made by animal research opponents. But it also features other false statements that have impeded America’s ability to respond to the global pandemic.
The video is titled “Debunking the Myths Surrounding COVID-19. ” It can be found on both YouTube and Vimeo. The links are below. AMP has also posted the clip on our COVID-19 resources pages and on all our social media channels including Facebook and Twitter.
We hope you take the time to watch. And if you like it, please share it on your social media channels.
A new study in Science Translational Medicine claims as many as 8.7 million Americans were infected with COVID-19 in March, but more than 80% of them were never diagnosed.
The estimate comes from a review of cases where patients went to the doctor with influenza-like illnesses that were never diagnosed as coronavirus, influenza or any of the other viruses that usually circulate in winter. Only 100,000 novel coronavirus cases were officially reported during that time period.
For the first time, a therapy has been shown to possibly improve the survival odds for patients suffering from the most severe cases of COVID-19. In a large study, the steroid drug dexamethasone was shown to reduce deaths by a third in patients hospitalized with the novel coronavirus. The full data has yet to be published.
Some experts quickly celebrated the results. However, others including surgeon, writer and public health researcher Atul Gawande has urged caution. He responded by tweeting, “after all the retractions and walk backs, it is unacceptable to tout study results by press release without releasing the paper.”
The National Institutes of Health today announced it has launched a centralized database to store and study medical record data generated from patients nationwide who have been diagnosed with the novel coronavirus. The program is part of the National COVID Cohort Collaborative (N3C). The effort aims to rapidly translate clinical information into increased knowledge about COVID-19 in order to better diagnose, track and treat the disease.
According to a press release issued today by the National Institutes of Health, researchers from the National Library of Medicine have identified key genomic features of SARS-CoV-2 that distinguish it from other members of the coronavirus family. The NIH says the research could be a crucial step in helping scientists develop approaches to predict, by genome analysis alone, the severity of future coronavirus disease outbreaks and detect animal coronaviruses that have the potential to infect humans.
Here’s a link to the NIH press release containing additional information.